The role of obinutuzumab in the management of follicular lymphoma

Future Oncol. 2019 Nov;15(31):3565-3578. doi: 10.2217/fon-2019-0193. Epub 2019 Sep 20.

Abstract

The outcomes for follicular lymphoma (FL) have improved significantly in recent years. This has been driven by an improved understanding of the pathobiology of FL and the development of therapeutic anti-CD20 antibodies. Combining rituximab with chemotherapy, coupled with its use as maintenance therapy, has contributed to significant improvements in disease control and progression-free survival. However, FL remains incurable and almost all patients invariably relapse. Therefore, there remains a need to develop novel therapeutic options and optimize existing regimens. Obinutuzumab (a first-in-class, glycoengineered, humanized type 2 anti-CD20 antibody) has been evaluated in a number of clinical trials. In this review, we will summarize the evaluable results of clinical trials investigating the efficacy of obinutuzumab in the treatment of FL.

Keywords: clinical trials; drug development; follicular lymphoma; immunotherapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, CD20 / metabolism
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor
  • Clinical Trials as Topic
  • Disease Management
  • Drug Evaluation, Preclinical
  • Humans
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / mortality
  • Molecular Targeted Therapy
  • Prognosis
  • Retreatment
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD20
  • Antineoplastic Agents, Immunological
  • Biomarkers, Tumor
  • obinutuzumab